Dr Maria Karasarides | Executive Director, ImmunoOncology
Regeneron Pharmaceuticals

Dr Maria Karasarides, Executive Director, ImmunoOncology, Regeneron Pharmaceuticals

Maria Karasarides, Ph.D. is an Executive Director, ImmunoOncology Development, at Regeneron Pharmaceuticals.  Prior to joining Regeneron, Dr. Karasarides was a senior leader in the ImmunoOncology Late Stage Clinical Group at AstraZeneca where she oversaw the clinical strategy and scientific development of novel immunotherapy based combinations with a key focus on identifying tumor-host interactions that propagate the anti-tumor immune response.  Dr. Karasarides’ experience spans academic research, medical affairs and clinical development with a special focus on immune-oncology.   Prior to joining AstraZeneca, Dr. Karasarides was a senior leader at early-stage companies within the Cambridge biotechnology hub, where she worked on the development of small molecule inhibitors, nanoliposomal chemotherapies and inducible gene therapy platforms across multiple tumor types.  Prior to that she was with Bristol-Myers Squibb, NJ, where she was an integral member of the ipilimumab (Yervoy®) team and played a key role in the approval of Yervoy®.  Yervoy® is approved by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), the Australian Therapeutic Goods Administration (TGA) and other Health Authorities, and is the first therapy to extend survival in metastatic melanoma.   She continued at Bristol-Myers Squibb as the brivanib Global Medical Lead, responsible for Global Medical Affairs Strategy, and later went on to establish and lead the US brivanib Medical Affairs team.  Before joining the pharmaceutical industry, Dr. Karasarides focused on the signaling mechanisms that drive and maintain oncogenic signaling validated through inducible/conditional mouse models and primary organotypic cultures.  During her tenure at the Institute of Cancer Research, London, UK, she worked with Richard Marais and Chris Marshall on BRAF mutations and delineated BRAF as a therapeutic target in melanoma.  Dr. Karasarides holds a Ph.D. in biology/biochemistry and conducted her graduate research at the Cleveland Clinical Foundation, Cleveland, OH focusing on RAS /PI3K signaling followed by post-doctoral fellowships at the Institute of Cancer Research, London, UK, and the Department of Molecular Medicine, University of Massachusetts Medical School, Boston, MA. 

Appearances:



Agenda Day 1 @ 12:15

The identification of tumor-host interactions that propagate an anti-tumor immune response

  • A deeper understanding of tumor-host interaction is essential for the development of effective immunotherapies
  • Designing successful clinical trials to identify responders and non-responders
  • Using the insight gained from clinical trials to identify which patients will benefit from which drug combinations

back to speakers